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Characterization of Extended-Spectrum b-Lactamases
Produced by Escherichia coli Isolated from Hospitalized
and Nonhospitalized Patients:
Emergence of CTX-M-15-Producing Strains
Causing Urinary Tract Infections
Annemieke Smet,1,2 An Martel,1 Davy Persoons,3,4 Jeroen Dewulf,3 Marc Heyndrickx,4 Geert Claeys,5
Marc Lontie,6 Britt Van Meensel,6 Lieve Herman,4 Freddy Haesebrouck,1,* and Patrick Butaye1,2,*
Extended-spectrum b-lactamase (ESBL)-producing Escherichia coli isolates were obtained from hospitalized and
nonhospitalized patients in Belgium betweenAugust 2006 andNovember 2007. The antimicrobial susceptibility of
these isolates was determined and their ESBL genes were characterized. Clonal relationships between the CTX-M-
producing E. coli isolates causing urinary tract infections were also studied. A total of 90 hospital- and 45 com-
munity-acquired cephalosporin-resistant E. coli isolates were obtained. Tetracycline, enrofloxacine, gentamicin,
and trimethoprim–sulfamethaxozole resistance rates were significantly different between the community-onset
and hospital-acquired isolates. A high diversity of different ESBLs was observed among the hospital-acquired
E. coli isolates, whereas CTX-M-15 was dominating among the community-acquired E. coli isolates (n¼ 28).
Thirteen different pulsed-field gel electrophoresis profiles were observed in the community-acquired CTX-M-15-
producing E. coli, indicating that multiple clones have acquired the blaCTX-M-15 gene. All community-acquired
CTX-M-15-producing E. coli isolates of phylogroups B2 and D were assigned to the sequence type ST131. The
hospital-acquired CTX-M-15-producing E. coli isolates of phylogroups B2, B1, A, and D corresponded to ST131,
ST617, ST48, and ST405, respectively. In conclusion, CTX-M-type ESBLs have emerged as the predominant class of
ESBLs produced by E. coli isolates in the hospital and community in Belgium. Of particular concern is the
predominant presence of the CTX-M-15 enzyme in ST131 community-acquired E. coli.
Introduction
B etalactams are extensively used in human medicine.
13
Acquired resistance to these antibiotics in gram-negative
bacteria is mainly mediated by bacterial b-lactamases and the
emergence of extended-spectrum b-lactamases (ESBLs) is of
great clinical importance. ESBLs have the ability to inactivate
most b-lactam antibiotics, including oxyimino-b-lactams
such as ceftazidime, ceftiofur, and aztreonam. They do not
hydrolyze cephamycins and carbapenems and they are in-
hibited by clavulanic acid.4 ESBL-producing bacteria, espe-
cially bacteria producing CTX-M enzymes, are worldwide
detected in various medical institutions.13,21 Originally,
ESBLs were mainly demonstrated in bacteria isolated from
patients hospitalized in intensive care units. Epidemics,
caused by these bacteria, starting in the intensive care units
and spreading to other parts of the hospital have been well
documented.9 Later on, CTX-M-producing Escherichia coli
from humans with urinary tract infections (UTIs) in the
community became more frequently described. Most of
these isolates are not only resistant to ceftriaxone, but also
to other commonly used first-line agents for UTIs, such as
trimethoprim–sulfamethoxazole, ciprofloxacin, gentamicin,
and nitrofurantoine.5,13,21
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Because of the increasing importance of multiresistant
ESBL-producing E. coli, clinicians should be aware of the pos-
sibility of treatment failures of serious infections caused by
these bacteria. Therefore, monitoring the prevalence of ESBL-
producing isolates and their antimicrobial susceptibility pro-
file at local, regional, or global level is required to develop
optimal ways to adapt clinical practices and to determine the
most effective agents and strategies for the treatment of in-
fections caused by these bacteria.13
The objectives of this study were to characterize the ESBLs
produced by nosocomial- and community-acquired E. coli
and to compare their antimicrobial susceptibility pattern.
The clonal relationships between CTX-M-producing E. coli
isolates causing UTIs were also studied.
Materials and Methods
Sampling
Between August 2006 and November 2007, 2266 E. coli
strains were consecutively isolated from samples of hospi-
talized and nonhospitalized patients in Belgium. E. coli from
hospitalized patients were isolated on tryptone soy agar
plates supplemented with ceftazidime (2mg=ml). The E. coli
from the community-onset UTI were isolated using the
standard procedure for urine cultures. Clinical data collected
with each referred isolate included whether the isolate was
considered to be hospital or community acquired. Hospital-
acquired isolates, collected at the Faculty of Medicine, Ghent
University, were defined as isolates from patients who had
been admitted >48 hr earlier. Community-acquired isolates
were defined as isolates from specimens referred from a
medical center serving only general practitioners in Leuven.
Antimicrobial susceptibility testing
and analysis of b-lactamases
The antimicrobial susceptibility of the E. coli isolates was
determined by the Kirby Bauer disk diffusion test using 21
antibiotic disks (Neo-sensitabs; Rosco Diagnostica, Taastrup,
Denmark) as described previously.18 Of these 21 tested an-
timicrobial agents, seven were b-lactams. Clinical Laboratory
Standards Institute (CLSI) guidelines (document M100-S17)
were followed for inoculum standardization, medium and
incubation conditions, and internal quality control organisms
(E. coliATCC 25922). The presence of an ESBLwas established
on the basis of the CLSI guidelines.7 Isoelectric focusing was
performed on crude enzyme extracts to determine the b-
lactamases present in each isolate. The ESBL gene was char-
acterized by polymerase chain reaction and sequencing as
described previously.18
Genetic background of CTX-M-producing strains
Clonal relatedness of E. coli carrying the predominant
CTX-M enzyme was established by pulsed-field gel electro-
phoresis (PFGE).1 The assignation of E. coli phylogenetic
groups was carried out by a multiplex polymerase chain
reaction assay as described previously.6 Multilocus sequence
typing (MLST) was performed using seven conserved
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and
recA) (www.mlst.ucc.ie).20 All fumC sequences from E. coli
isolates belonging to phylogroup D were analyzed for a
C288T single-nucleotide polymorphism.8
Statistical analysis
The analysis of variance test was used for analysis of mean
differences in antimicrobial resistance between community-
onset and nosocomial isolates and between different CTX-M-
producing strains. All analyses were performed using SPSS,
version 16 (SPSS, Chicago, IL).
Results
Of the 2266 isolates that were screened, a total of 135 (6%)
cephalosporin-resistant E. coli isolates were identified. All
isolates were unduplicated consecutive ESBL-producing
Table 1. Number and Percentage of Resistances to b-Lactam and Non-b-Lactam Antimicrobials
of Cephalosporin-Resistant Escherichia coli Isolated from Hospitalized and Nonhospitalized Patients
Number (%) of resistant strains
Antimicrobial agentsa
E. coli (n¼ 45)
Hospital, nonurine samples
E. coli (n¼ 45)
Hospital, urine samples




Amoxicillin–clavulanic acid 0 (0) 0 (0) 12 (26.7) 9 (21)
Ceftazidime 42 (93) 24 (53.3) 15 (33.3) 22 (51.2)
Cefepime 44 (97.6) 29 (64.4) 21 (46.7) 26 (60.5)
Ceftriaxone 45 (100) 41 (91) 39 (87) 39 (90.7)
Azteonam 31 (70) 29 (64) 21 (46.7) 27 (62.8)
Kanamycin 17 (38.1) 12 (26.7) 11 (24.4) 6 (14)
Gentamicin 10 (21.4) 2 (4.4) 13 (28.9) 13 (30.2)
Streptomycin 19 (42.9) 11 (24.4) 2 (4.4) 8 (18.6)
Neomycin 10 (23.8) 5 (11.1) 8 (17.8) 7 (16.27)
Tetracycline 33 (73.8) 35 (77.8) 25 (55.6) 26 (60.5)
Nalidixic acid 22 (48.8) 30 (66.7) 42 (93.3) 42 (97.2)
Enrofloxacin 20 (45) 25 (55.6) 37 (82) 36 (83.7)
Trimethoprim 32 (71.4) 36 (80) 20 (44.4) 18 (41.9)
Sulphonamides 34 (76.2) 41 (91) 25 (55.6) 22 (51.2)
aNone of the 135 isolates showed resistance to imipenem and only 1 (2%) community-acquired E. coli isolate showed resistance to cefoxitin.
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E. coli collected from 90 hospitalized (hospital-acquired) and
45 nonhospitalized (community-acquired) patients. Of these
hospital-acquired E. coli, 45 were from urine samples and 45
from nonurine samples. The latter originated from wounds
(n¼ 17, 37.8%), sputum (n¼ 17, 37.8%), and blood cultures
(n¼ 11, 24.4%). The 45 community-acquired isolates origi-
nated from urine samples from humans with UTIs.
A summary of results of disk diffusion tests of hospital-
acquired and community-acquired E. coli is shown in Table
1. Resistance to enrofloxacin was present in 82 (60.7%), na-
lidixic acid resistance in 94 (69.6%), tetracycline resistance
in 93 (69%), and trimethoprim–sulfamethoxazole resistance
in 112 (83%) of the 135 isolates. Gentamicin, streptomycin,
neomycin, and kanamycin resistances were present in 25
(18.5%), 32 (24%), 23 (17%), and 40 (29.6%) of the 135 isolates,
respectively. Several differences in antimicrobial resistance
profileswere seen between hospital-acquired and community-
acquired E. coli as indicated in Table 2.
Of the 135 E. coli isolates, 123 isolates were multidrug
resistant showing resistance to two or more non-b-lactam
antimicrobial agents. Four percent of the isolates showed
only resistance to b-lactams, 5% of the isolates were resistant
to one additional antimicrobial agent, and the other 91%
were resistant to at least two or more antimicrobials (data not
shown).
The distribution of different ESBLs among nosocomial-
(urine and nonurine samples) or community-acquired E. coli
isolates from humans in Belgium is shown in detail in Table 3.
Seventy two (53%) of 135 were positive for CTX-M-1-like b-
lactamases (CTX-M-1, CTX-M-15), 10 (7.5%) were positive for
CTX-M-2-like b-lactamases (CTX-M-2), 20 (15%) were posi-
tive for CTX-M-9-like b-lactamases (CTX-M-9 and CTX-M-
14), and 32 (24%) were negative for CTX-M enzymes. These
isolates carried b-lactamases from the TEM family or SHV
family. Table 3 shows a high diversity of different ESBLs
among the hospital-acquired E. coli isolates. However, among
the community-acquired E. coli isolates, the CTX-M-15 en-
zyme belonging to the CTX-M-1-like b-lactamases was domi-
nating (n¼ 28, 62%). It has to be noted that more than half
of the CTX-M-15 producing E. coli (hospital- and community-
acquired) isolateswere resistant to tetracyclines, nalidixic acid,
and enrofloxacin (Table 1).
PFGE was used to assess the diversity of the community-
acquired E. coli isolates producing CTX-M-15, to determine if
the community-acquired UTIs were caused by one single
clone producing this enzyme. Similarity among profiles was
determined by cluster analysis in a dendrogram using the
cutoff of at least 80%. Thirteen different clusters were ob-
served (Fig. 1). Some strains were clonally related because
they differed only by one or few bands (Fig. 1).
To establish the clonal relationships between the nosoco-
mial- (n¼ 14) and community-acquired (n¼ 28) CTX-M-15-
producing E. coli isolates causing UTIs, phylogenetic groups
were determined andMLSTwas performed. The community-
acquired CTX-M-15-producing E. coli isolates belonged to
phylogroups B2 (91%) and D (9%), whereas the nosocomial-
acquired CTX-M-15-producing E. coli isolates belonged to
Table 2. Significant Differences ( p< 0.05)
in the Prevalence of Acquired Antimicrobial
Resistances Between Community- and Nosocomial-
Acquired Extended-Spectrum b-Lactamase-Producing
Escherichia coli










Tetracycline 25 (55.6) 68 (75.8) 0.018
Enrofloxacin 37 (82.2) 45 (50) <0.0001
Gentamicin 13 (28.9) 8 (9) 0.002
Trimethoprim–
sulfamethoxazole
28 (62) 79 (88) 0.001
Table 3. Distribution of Extended-Spectrum b-Lactamases Among 135 Cephalosporin-Resistant
Escherichia coli Isolated from Hospitalized and Nonhospitalized Patients
Number (%) of isolates
Enzyme b-Lactamase
E. coli (n¼ 45)a
Hospital, nonurine
samples
E. coli (n¼ 45)b
Hospital, urine
samples
E. coli (n¼ 45)c
Community, urine
samples Total (%)
Narrow spectrum b-lactamase TEM-1 21 (46.7) 9 (20) 23 (51.1) 53 (39.3)
OXA-1d 0 (0) 5 (11.1) 15 (33.3) 20 (14.8)
ESBL TEM-16 0 (0) 1 (2.2) 0 (0) 1 (1)
TEM-24 6 (13) 4 (8.9) 0 (0) 10 (7.5)
TEM-52 3 (6.7) 1 (2.2) 0 (0) 4 (3)
SHV-12 13 (28.9) 1 (2.2) 3 (6.7) 17 (12.6)
CTX-M-1 9 (20) 12 (26.7) 8 (17.8) 29 (21.5)
CTX-M-2 6 (13.3) 4 (8.9) 0 (0) 10 (7.5)
CTX-M-9 2 (4.4) 1 (2.2) 0 (0) 3 (2.3)
CTX-M-14 4 (8.9) 7 (15) 6 (13) 17 (12.6)
CTX-M-15 1 (2.2) 14 (31.1) 28 (62.2) 43 (32)
aTwo E. coli isolates had both SHV-12 and CTX-M-15 and one had both SHV-12 and TEM-24.
bOne E. coli isolate had both SHV-12 and CTX-M-1, and one had both SHV-12 and CTX-M-15.
cOne E. coli isolate had both SHV-12 and CTX-M-14.
dE. coli isolates that had OXA-1 enzyme produced also CTX-M-15 enzyme.
ESBL, extended-spectrum b-lactamase.
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phylogroups B2 (22%), B1 (11%), A (44%), and D (23%). All
community-acquired E. coli isolates of phylogroups B2 and
D were assigned to the sequence type (ST) ST131. All nos-
ocomial-acquired E. coli isolates of phylogroups B2, B1, A,
and D corresponded to ST131, ST617, ST48, and ST405, re-
spectively. The C288T single-nucleotide polymorphism in
the fumC gene was absent in the strains belonging to phylo-
group D.
Statistical analysis of the 135 isolates revealed that isolates
containing a CTX-M-2 gene were less frequently resistant to
tetracycline than isolates harboring a CTX-M-9-like gene
(CTX-M-9, CTX-M-14) (12 [60%] of 20 vs. 10 [100%] of 10,
p¼ 0.02). Enrofloxacine resistance was significantly higher
in CTX-M-1-like (CTX-M-1, CTX-M-15) than in CTX-M-2-
containing strains (48 [65%] of 73 vs. 3 [30%] of 10, p¼ 0.04).
Discussion
More than half of the isolates included in this study were
resistant to enrofloxacin, tetracycline, and trimethoprim–
sulfamethoxazole. Acquired resistance to aminoglycosides
was also often present. These results confirm that ESBL-
producing E. coli are often multiresistant, which may jeop-
ardize clinical efficacy of antimicrobial treatment of infections
caused by these microorganisms.
Our study included clinical E. coli isolates from both hos-
pital and community sites. The percentage of acquired resis-
tance to tetracycline and trimethoprim–sulfamethaxozole was
significantly higher in hospital-acquired isolates, whereas
community-acquired isolates were more often resistant to
enrofloxacin and gentamicin. The reason for this finding is not
clear. Epidemiological studies taking into account antimicro-
bial usage in the patient populations included in our study
may help to explain these differences.
Several countries have reported the presence of different
CTX-M enzymes among hospital-acquired E. coli isolates,
including CTX-M-1, CTX-M-2, CTX-M-9, CTX-M-14, and
CTX-M-15.2,5,8,11 Similar findings were found among our
hospital-acquired isolates.
In most studies worldwide, CTX-M-15 was the most
common enzyme among clinical community-acquired E. coli
isolates causing UTIs.3,9,10,12,13 Also, in our study, CTX-M-15
FIG. 1. Dendrogram generated by Bionumerics software (Applied Maths, Kortrijk, Belgium), showing the results of cluster
analysis on the basis of pulsed-field gel electrophoresis fingerprinting (with XbaI). Similarity analysis was performed using
Pearson coefficient (optimal 1%, tolerance 1%), and clustering was done by the unweighted-pair group method using average
linkages. The gray line shows the delineation line of 80%. The different pulsed-field gel electrophoresis profiles and isolate
numbers, carrying a CTX-M-15 enzyme, are indicated. All isolates were community acquired with the exception of B24,
which was nosocomially acquired.
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was clearly themost prevalent enzyme among the community-
acquired E. coli causing UTIs.
Distinct PFGE profileswere detected among the community-
acquired CTX-M-15-positive strains, indicating that the pre-
dominant presence of enzyme in community-acquired E. coli
causing UTIs is not due to the spread of a single E. coli clone.
CTX-M-encoding genes have been shown to be located on a
plasmid,19,22 which may have been transmitted to different E.
coli strains.
MLST revealed that all these isolates belonged to ST131.
Clonal outbreaks of E. coli corresponding to the ST131 have
already been reported in several countries.11,12,14–17
Several phylogroups and STs were found in our collection
of nosocomial-acquired E. coli isolates causing UTIs. Phy-
logroups B2 and D are known to be associated with the
hospital setting. The ST types ST131 and ST405 belonging to
B2 and D, respectively, have already been described among
CTX-M-15-producing E. coli isolated from hospitalized pa-
tients.2,8,14 Nosocomial-acquired CTX-M-15-producing E. coli
isolates corresponding to ST48 and ST617 have, to our
knowledge, not yet been described.
An evolutionary convergent relationship among ST131
and the plasmids carrying the blaCTX-M-15 gene could explain
successful dissemination of CTX-M-15-carrying plasmids
within this E. coli lineage as mentioned previously.8 Mole-
cular characterization of CTX-M-15-carrying plasmids is
necessary to obtain better insights into the molecular epide-
miology of the CTX-M-15 gene in E. coli.
More thanhalf of thenosocomial-acquired isolates included in
our study produced a CTX-M enzyme. This confirms that CTX-
M enzymes, which can be seen as community ESBL producers,
have also taken their entry into hospital-acquired11 E. coli.
In conclusion, this is the first detailed documentation of the
diversity of ESBLs among E. coli isolates obtained from hos-
pitalized and nonhospitalized patients in Belgium. Of parti-
cular concern is the predominant presence of the CTX-M-15
enzyme in community-acquiredE. coli corresponding toST131.
Acknowledgments
The authors thank all laboratory and clinical staff of the
Department of Clinical Microbiology from the Faculty of
Medicine in Ghent, Belgium, for contributing to the national
surveillance. They also thank Danielle Vandergheynst for her
skilled technical assistance. This work was supported by a
grant of Federal Public Service of Health, Food Chain Safety
and Environment (grant no. RT 06=3 ABRISK).
Disclosure Statement
No competing financial interest exists.
References
1. Bertrand, S., F.X. Weill, A. Cloeckaert, M. Vrints, E.
Mairiaux, K. Praud, K. Dierick, C. Wildemauve, C.
Godard, P. Butaye, H. Imbrechts, P.A. Grimont, and J.M.
Collard. 2006. Clonal emergence of extended-spectrum
beta-lactamase (CTX-M-2)-producing Salmonella enterica
serovar Virchow isolates with reduced susceptibilities to
ciprofloxacin among poultry and humans in Belgium and
France (2000 to 2003). J. Clin. Microbiol. 44:2897–2903.
2. Blanco, M., M.P. Alonso, M.H. Nicolas-Chanoine, G.
Dahbi, A. Mora, J.E. Blanco, C. Lopez, P. Cortes, M. Lla-
gostera, V. Leflon-Guibout, B. Puentes, R. Mamani, A.
Herrera; M.A. Coire, F. Garcia-Garotte, J.M. Pita, and J.
Blanco. 2009. Molecular epidemiology of Escherichia coli
producing extended-spectrum b-lactamases in Lugo (Spain):
dissemination of clone O25b:H4-ST131 producing CTX-M-
15. J. Antimicrob. Chemother. 63:1135–1141.
3. Bonnet, R. 2004. Growing group of extended-spectrum beta-
lactamases: the CTX-M enzymes. Antimicrob. Agents Che-
mother. 48:1–14.
4. Bradford, P.A. 2005. b-Lactamases in the 21st century:
characterization, epidemiology and detection of this impor-
tant resistance threat. Clin. Microbiol. Rev. 14:933–951.
5. Brigante, G., F. Luzzaro, M. Perilli, G. Lombardi, A. Coli,
G.M. Rossolini, G. Amicosante, and A. Toniolo. 2005.
Evolution of CTX-M-type beta-lactamases in isolates of
Escherichia coli infecting hospital and community patients.
Int. J. Antimicrob. Agents 25:157–162.
6. Clermont, O., S. Bonacorsi, and E. Bingen. 2000. Rapid and
simple determination of the Escherichia coli phylogenetic
group. Appl. Environ. Microbiol. 66:4555–4558.
7. Clinical and Laboratory Standards Institute. 2007. Perfor-
mance Standards for Antimicrobial Susceptibility Testing:
Seventeenth Informational Supplement M100-S17. CLSI,
Wayne, PA.
8. Coque, T.M., A. Novais, A. Carattoli, L. Poirel, J. Pitout, L.
Peixe, F. Baquero, R. Canton, and P. Nordmann. 2008.
Dissemination of clonally related Escherichia coli strains ex-
pressing extended-spectrum b-lactamase CTX-M-15. Emerg.
Infect. Dis. 14:195–200.
9. Gori, A., F. Espinasse, A. Deplano, C. Nonhoff, M.H.
Nicolas, and M.J. Struelens. 1996. Comparison of pulsed-
field gel electrophoresis and randomly amplified DNA
polymorphism analysis for typing extended-spectrum-beta-
lactamase producing Klebsiella pneumoniae. J. Clin. Microbiol.
34:2448–2453.
10. Karim, A., L. Poirel, S. Nagarajan, and P. Nordmann. 2001.
Plasmid-mediated extended-spectrum b-lactamase (CTX-M-
3 like) from India and gene association with insertion
sequence ISEcp1. FEMS Microbiol. Lett. 201:237–241.
11. Lavollay, M., K. Mamlouk, T. Frank, A. Akpabie, B.
Burghoffer, S. Ben Redjeb, R. Bercion, V. Gautier, and G.
Arlet. 2006. Clonal dissemination of a CTX-M-15 b-lactamase-
producing Escherichia coli strain in the Paris area, Tunis and
Bangui. Antimicrob. Agents Chemother. 50:2433–2438.
12. Mushtaq, S., N. Woodford, N. Potz, and D.M. Livermore.
2003. Detection of CTX-M-15 extended-spectrum b-lactamase
in theUnitedKingdom. J. Antimicrob. Chemother. 52:528–529.
13. Pitout, J.D.D., and K.B. Laupland. 2008. Extended-
spectrum b-lactamase-producing Enterobacteriaceae: an emerg-
ing public-health concern. Lancet 8:159–166.
14. Pitout, J.D.D., D.B. Gregson, L. Campbell, and K.B.
Laupland. 2009. Molecular characteristics of extended-
spectrum b-lactamase-producing Escherichia coli causing
bacteraemia in the Calgary Health Region 2000–07: the
emergence of clone ST131 as a cause of community-acquired
infections. Antimicrob. Agents Chemother. 53:2846–2851.
15. Pitout, J.D.D., K.B. Laupland, D.L. Church, M.L. Menard,
and J.R. Johnson. 2005. Virulence factors of Escherichia
coli isolates that produce CTX-M-type extended-spectrum
b-lactamases. Antimicrob. Agents Chemother. 49:4667–4670.
16. Ruppe´, E., S. Hem, S. Lath, V. Gautier, F. Ariey, J.L. Sar-
thou, D. Monchy, and G. Arlet. 2009. CTX-M b-lactamases
in Escherichia coli from community-acquired urinary tract
infections, Cambodia. Emerg. Infect. Dis. 15:741–747.
HOSPITAL- VERSUS COMMUNITY-ACQUIRED ESBLs 133
17. Sidjabat, H.E., D.L. Paterson, J.M. Adams-Haduch, L.
Ewan, A.W. Pasculle, C.A. Muto, G.B. Tian, and Y. Doi.
2009. Molecular epidemiology of CTX-M-producing Escher-
ichia coli at a Tertiary medical center in Western Pennsyl-
vania. Antimicrob. Agents Chemother. 53:4733–4739.
18. Smet, A., A. Martel, D. Persoons, J. Dewulf, M. Heyn-
drickx, B. Catry, L. Herman, F. Haesebrouck, and P. Bu-
taye. 2008. Diversity of extended-spectrum b-lactamases and
class C b-lactamases among cloacal Escherichia coli in Belgian
broiler farms. Antimicrob. Agents Chemother. 52:1238–1243.
19. Smet, A., A. Martel, D. Persoons, J. Dewulf, M. Heyn-
drickx, A. Cloeckaert, K. Praud, G. Claeys, B. Catry, L.
Herman, F. Haesebrouck, and P. Butaye. 2009. Compara-
tive analysis of extended-spectrum-b-lactamase (ESBL)-
carrying plasmids fromdifferentmembers ofEnterobacteriaceae
isolated from poultry, pigs and humans: evidence for a shared
b-lactam resistance gene pool? J. Antimicrob. Chemother.
63:1286–1288.
20. Tartof, S.Y., O.D. Solberg, A.R. Manges, and L.W. Riley.
2005. Analysis of a uropathogenic Escherichia coli clonal
group by multilocus sequence typing. J. Clin. Microbiol.
43:5860–5864.
21. Walter-Rasmussen, J., and N. Hoiby. 2004. Cefotaximases
(CTX-M-ases), an expanding family of extended-spectrum b-
lactamases. Can. J. Microbiol. 50:137–165.
22. Wiener, J., J.P. Quinn, P.A. Bradford, R.V. Goering, C.
Nathan, K. Bush, and R.A. Weinstein. 1999. Multiple




Department of Pathology, Bacteriology, and Avian Diseases






134 SMET ET AL.
This article has been cited by:
1. Juyoun Shin, Dae Hun Kim, Kwan Soo Ko. 2011. Comparison of CTX-M-14- and CTX-M-15-producing Escherichia coli
and Klebsiella pneumoniae isolates from patients with bacteremia. Journal of Infection . [CrossRef]
2. Nevine Fam , Véronique Leflon-Guibout , Salwa Fouad , Laila Aboul-Fadl , Estelle Marcon , Doaa Desouky , Inas El-
Defrawy , Aisha Abou-Aitta , John Klena , Marie-Hélène Nicolas-Chanoine . 2011. CTX-M-15-Producing Escherichia coli
Clinical Isolates in Cairo (Egypt), Including Isolates of Clonal Complex ST10 and Clones ST131, ST73, and ST405 in Both
Community and Hospital SettingsCTX-M-15-Producing Escherichia coli Clinical Isolates in Cairo (Egypt), Including Isolates
of Clonal Complex ST10 and Clones ST131, ST73, and ST405 in Both Community and Hospital Settings. Microbial Drug
Resistance 17:1, 67-73. [Abstract] [Full Text] [PDF] [PDF Plus]
3. Umaer Naseer , Arnfinn Sundsfjord . 2011. The CTX-M Conundrum: Dissemination of Plasmids and Escherichia coli
ClonesThe CTX-M Conundrum: Dissemination of Plasmids and Escherichia coli Clones. Microbial Drug Resistance 17:1,
83-97. [Abstract] [Full Text] [PDF] [PDF Plus]
4. Stephen E Mshana, Can Imirzalioglu, Torsten Hain, Eugen Domann, Eligius F Lyamuya, Trinad Chakraborty. 2011. Multiple
ST clonal complexes, with a predominance of ST131, of Escherichia coli harbouring blaCTX-M-15 in a tertiary hospital in
Tanzania. Clinical Microbiology and Infection no-no. [CrossRef]
5. Maurine A. Leverstein-van Hall, Cindy M. Dierikx, James Cohen-Stuart, Guido M. Voets, Thijs M. P. van den Munckhof,
Alieda van Essen-Zandbergen, Tamara Platteel, Ad C. Fluit, Nienke van de Sande - Bruinsma, Jelle Scharinga, Marc J.M.
Bonten, Dik J. Mevius. 2011. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and
strains. Clinical Microbiology and Infection no-no. [CrossRef]
6. B. A. Rogers, H. E. Sidjabat, D. L. Paterson. 2010. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-
associated strain. Journal of Antimicrobial Chemotherapy . [CrossRef]
7. Esragul Akinci, Haluk Vahaboglu. 2010. Minor extended-spectrum #-lactamases. Expert Review of Anti-infective Therapy
8:11, 1251-1258. [CrossRef]
8. H. Rodriguez-Villalobos, P. Bogaerts, C. Berhin, C. Bauraing, A. Deplano, I. Montesinos, R. de Mendonca, B. Jans, Y.
Glupczynski. 2010. Trends in production of extended-spectrum  -lactamases among Enterobacteriaceae of clinical interest:
results of a nationwide survey in Belgian hospitals. Journal of Antimicrobial Chemotherapy . [CrossRef]
